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Regulation of urokinase receptor function and pericellular 
proteolysis by the integrin α5β1 
Rosemary Bass; Vincent Ellis 
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Summary  
Interactions between the uPA receptor (uPAR) and various inte-
grins, including α5β1, are known to modulate integrin-dependent 
cell adhesion, and we have shown that the integrin-associated 
tetraspanin protein CD82 down-regulates uPAR-dependent 
plasminogen activation by affecting α5β1 cellular localisation. 
Here we have investigated whether overexpression of α5β1 di-
rectly affects uPAR-dependent pericellular proteolysis. CHO 
cells overexpressing α5β1 were found to activate plasminogen at 
a rate up to 18-fold faster than B2CHO cells which are α5-defi-
cient. This effect was dependent on the activation state of α5β1, 
as it was maximal in the presence of Mn2+. To determine the role 
of uPAR-α5β1 interactions in this effect, we determined the ad-
hesion of these cells to immobilised soluble uPAR (suPAR). 
Neither cell-type was found to adhere to suPAR, but both cell 
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types were found to adhere to an anti-uPAR monoclonal anti-
body in a uPAR- and integrin-dependent manner. This adhesion 
was 10-fold greater in the absence of α5β1, possibly implicating 
the involvement of non-α5-integrins. Soluble forms of the vari-
ous components were used to investigate the molecular basis of 
these effects, but no direct interactions could be demonstrated 
between α5β1 and either uPAR, uPA or uPA-uPAR complex. This 
suggests that assembly of these components on the plasma 
membrane is required to influence uPAR function, increasing 
uPAR-dependent pericellular proteolysis and decreasing uPAR-
dependent cell adhesion. These interactions may be modified by 
other integrins, suggesting a complex interplay between uPAR 
and integrins on the cell surface with the potential to regulate in-
vasive cell migration.  
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Introduction 
The binding of urokinase-type plasminogen activator (uPA) to its 
specific cell surface receptor uPAR promotes generation of plas-
min in the pericellular environment (1–4). In this compartment 
plasmin is involved in the proteolytic modification of the extra-
cellular matrix (ECM), removing physical barriers to cell mi-
gration and further activating latent growth factors and matrix 
metalloproteases in the ECM (5, 6). In this way plasmin is able to 
influence cell migration in the pathogenesis of disease states in-
cluding atherosclerosis and cancer (7). Degradation of ECM 
components by plasmin impacts on the highly regulated interac-
tions between the ECM and the cytoskeleton, which are me-
diated through cell surface receptors of the integrin family. In ad-
dition to regulating plasmin generation, uPAR is also able to alter 
how cells interact with the ECM by affecting integrin function 
(8–12) and by direct interactions with vitronectin (13–15). The 
integrin α5β1 is of particular interest as putative interactions be-
tween this integrin and uPAR have also been linked to uPAR-me-
diated signalling events (16–19). 
We have presented evidence for another level at which the 
cell surface systems mediating proteolysis and adhesion are co-
ordinated. We found that expression of the tetraspanin protein 
CD82 in a normal breast epithelial cell line led to 50-fold reduc-
tion in uPAR-mediated plasminogen activation despite unaltered 
expression of uPA or uPAR (20). CD82 was found to cause a red-
istribution of α5β1 and uPAR, leading to their colocalisation at 
sites of focal adhesion and physical association as demonstrated 
by co-immunoprecipitation. Therefore, under these conditions, 
uPAR was rendered cryptic, i.e. unable to bind uPA, when associ-
ated with α5β1. The potential significance of this has led us to in-
vestigate the interaction between uPAR and α5β1 and its con-
sequences for uPAR function. 
In the present study we show that uPAR function can be 
modulated by expression of exogenous α5β1 integrin in Chinese 
hamster ovary (CHO) cells and that this involves cooperation 
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with endogenous integrins present on the cell surface. Ex-
pression of α5β1 led to a increase in uPAR-dependent plas-
minogen activation, suggesting that here α5β1 promotes uPA-
uPAR interactions. However, uPAR-dependent adhesion of these 
cells to an immobilised anti-uPAR monoclonal antibody was 
only observed in the absence of α5β1, suggesting that multiple in-
tegrins can differentially affect uPAR function. Furthermore, we 
find that the effects of α5β1 cannot be recapitulated with purified 
proteins, demonstrating that these interactions are dependent on 
assembly of the components on the cell surface. 
Materials and methods 
Cell lines, antibodies and proteins 
CHO cells stably expressing the human α5-integrin subunit 
(α5CHO, clone #17) (21) were kindly provided by Prof. Yoshika-
zu Takada (The Scripps Research Institute, San Diego, CA, 
USA). α5β1-deficient B2 variant CHO cells (B2CHO) (22) were 
kindly provided by Prof. Rudy Juliano (University of North Ca-
rolina, Chapel Hill, NC, USA). Cells were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM), supplemented with 
10% (v/v) foetal calf serum (FCS) and 0.1 mM non-essential 
amino acids. All cell culture reagents including ECM com-
ponents were from Invitrogen (Paisley, UK). An isolated 50 kDa 
fragment of fibronectin containing the integrin binding site and 
recombinant α5β1 integrin proteins were kindly provided by 
Prof. Martin Humphries (University of Manchester, UK) (23). 
These comprised the ectodomain of α5β1 prepared as a fusion 
with a human γ1 Fc domain to promote heterodimer formation 
(α5β1-Fc) and α5β1 with the fusion partner removed. The mono-
clonal antibodies to uPA (clone 5) and uPAR (R4) were kindly 
provided by Dr. Gunilla Høyer-Hansen (Finsen Laboratory, Co-
penhagen, Denmark). Secondary antibodies were from Dako 
(Ely, UK). Soluble recombinant uPAR (suPAR) residues 1–277 
expressed in Drosophila S2 cells was kindly provided by Dr. Mi-
chael Ploug (Finsen Laboratory). Pro-uPA produced by the 
human kidney cell line TCL-598 and DFP-inactivated uPA were 
as previously described (1, 24). Lys-plasminogen was from 
Enzyme Research Laboratories (Swansea, UK). The peptide 
M25 (9) was prepared by solid phase synthesis. Phosphatidyli-
nositol-specific phospholipase C (PI-PLC) was from Sigma (St 
Louis, MO, USA). 
Cell surface plasminogen activation 
Plasminogen activation by uPA bound to uPAR on the surface of 
CHO cells was determined as previously described (2). Briefly, 
cells were grown to confluence in 48-well plates, washed with 
phosphate-buffered saline (PBS) to remove unbound uPA and in-
cubated at 37oC with Lys-plasminogen (120 nM) and the plasmin 
specific fluorogenic substrate H-D-Val-Leu-Lys-AMC 
(250 µM). Plasmin generation by the endogenously bound uPA 
was measured continuously as change in fluorescence in a Spec-
traMAX Gemini microplate reader (Molecular Device, Sunny-
vale, CA, USA) at excitation and emission wavelengths of 360 
and 440 nm, respectively. Plasmin concentration was determined 
as δF and plasmin generation represented as δF versus time by 
reference to standard curves of active-site titrated plasmin. In 
some experiments endogenously bound uPA was removed by 
brief treatment with 0.1M glycine/pH 3.0 prior to incubation 
with pro-uPA (2 nM) for 20 minutes (min) at 37oC and further 
washing. 
Cell adhesion assays 
The method used for cell adhesion assays was based on that de-
scribed by (25). Briefly, 96-well plates were coated with either fi-
bronectin (10 nM), suPAR (50 nM), the anti-uPAR monoclonal 
antibody R4 (50 nM) or isotype-matched control IgG at the indi-
cated concentrations in coating buffer (15mM Na2CO3/35mM 
NaHCO3/pH 9.6), for 15 hours (h) at 4oC. After washing with 
PBS, wells were blocked with 1% bovine serum albumin (BSA)/
PBS for 30 min at 37oC. Wells were washed again with PBS prior 
to plating the CHO cells at a density of 1 x 105 per well in Hepes-
Tyrode buffer (10 mM Hepes/150 mM NaCl/12 mM 
NaHCO3/0.4 mM NaH4PO4/2.5 mM KCl/0.1% (w/v) glu-
cose/0.02% (w/v) BSA/2 mM MgCl2) in the presence or absence 
of 0.1 mM MnCl2. Cells were incubated at 37oC for 1 h, washed 
with PBS, fixed with 4% (v/v) formaldehyde for 10 min at room 
temperature and stained with Methylene Blue in 10 mM sodium 
borate buffer for 30 min at room temperature. Wells were washed 
extensively with water, the cell-bound dye released in 50% (v/v) 
ethanol/0.1% (v/v) HCl and absorbance measured at 650 nm in a 
ThermoMAX microplate reader (Molecular Device). 
Preparation of cell lysates, immunoprecipitation, 
Western blotting and ligand blotting 
Cell lysates were prepared by washing sub-confluent monolayers 
twice with PBS prior to harvesting in PBS containing complete 
EDTA-free inhibitors (Roche). Cells were lysed at 5x107 cell/ml 
in 50 mM Hepes pH 7.8/150 mM NaCl containing 1% (v/v) Tri-
ton X-100 and protease inhibitors. After 30 min on ice, insoluble 
material was pelleted by centrifugation at 2,000g for 5 min at 
4oC. The protein content of the soluble fractions was measured 
with a BCA protein assay kit according to the manufacturer’s in-
structions (Pierce). 
Immunoprecipitation was carried out essentially as de-
scribed previously (20). Briefly, 100 µl aliquots of fractions pre-
cleared with Protein G-Sepharose were incubated with 30 pmole 
of anti-uPAR R4 or isotype matched IgG for 12 h at 4oC. Fifty µl 
of 50% (v/v) Protein G-Sepharose was added to each sample, 
and immune complexes allowed to bind for at least 1 h at 4°C. 
The beads were washed four times with lysis buffer, and ad-
sorbed material eluted in non-reducing Laemmli sample buffer. 
For Western and ligand blotting, samples separated by PAGE 
were transferred to PVDF membranes (Bio-Rad). Protein bands 
were detected by incubation with the appropriate antibody fol-
lowed by HRP-conjugated secondary antibodies (0.65 µg/ml). 
For ligand blotting to detect endogenous CHO uPAR, the anti-
body incubations were preceded by an incubation with 2 nM pro-
uPA. 
Solid phase binding assays 
Plates with 96 wells were coated with α5β1-Fc, uPA or suPAR at 
the indicated concentrations in coating buffer, for 15 h at 4oC. 
Wells were blocked with 5% BSA in PBS containing either 0.1 
mM MnCl2 or 0.1mM EDTA, for 1 h at room temperature with 
agitation. Wells were then washed three times with PBS/0.1% 
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(v/v) Tween20. The defined protein samples were prepared in 
0.05% (v/v) BSA/PBS with MnCl2 or EDTA and plated for incu-
bation for 1 h as before. Following further washing the primary 
antibodies were applied at 5 µg/ml in 0.05% (v/v) BSA/PBS with 
MnCl2 or EDTA and incubated as before. This was repeated with 
the HRP-conjugated secondary antibody, used at 0.65 µg/ml. 
After a final washing step the plate was developed by the addi-
tion of 100 µl of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate 
system (Sigma) per well. Colour was allowed to develop for 10 
min and the reaction stopped by the addition of 1M H2SO4. Ab-
sorbance was measured at 450 nm in a ThermoMAX microplate 
reader (Molecular Devices). 
Native PAGE 
Native or non-denaturing PAGE was performed according to the 
method of Liou and Willison (26). Briefly, equimolar com-
binations of uPA, suPAR, α5β1 and α5β1-Fc were incubated in 
Tris-buffered saline (TBS) at 4oC for 10 min prior to separation 
on a pH 8.8, 6% polyacrylamide gel at 4oC. 
Silver staining 
Native gels were stained with 0.25% (w/v) Coomassie Brilliant 
Blue G250/45% (v/v) methanol/10% (v/v) glacial acetic acid for 
5 min and destained (45% (v/v) methanol/10% (v/v) glacial 
acetic acid) for 12 h. Gels were washed in water for 15 min prior 
to incubation for 5 min with a small amount of 
K3Fe(CN)6/NaS2O3 in a 5:8 ratio dissolved in water. Gels were 
washed in water, incubated with 12 mM AgNO3 for approxi-
mately 20 min, and further washed in water for 5 min. To devel-
op the silver stain, gels were briefly washed with 270 mM 
Na2CO3 and then incubated in 270 mM Na2CO3/0.2% (v/v) for-
maldehyde until bands had developed; the reaction was stopped 
with 5% (v/v) acetic acid. All procedures were carried out at 
room temperature. 
Statistical analysis 
Data are presented as mean ± standard deviation (SD). Signifi-
cance was assessed using Student’s t-test. 
Results 
We have previously shown that expression of CD82 leads to a 
50-fold reduction in uPA-catalysed plasminogen activation, con-
comitant with a redistribution, colocalisation and physical as-
sociation between uPAR and α5β1 integrin (20). Here we have di-
rectly investigated the effect of α5β1 on uPAR function, using 
CHO cells expressing different levels of α5β1. α5CHO are trans-
fected with the human α5-integrin subunit, and have a chimera of 
human α5 coupled with endogenous β1 on their surface (21). 
B2CHO are essentially α5 null, containing only 2% of the α5β1 
found in parental cells (22). 
α5β1 promotes uPAR-mediated plasminogen activation 
on CHO cells 
Plasminogen activation by uPAR-bound uPA on the surface of both 
α5CHO and B2CHO cells was determined. These experiments 
were performed both in the presence and absence of Mn2+, which 
alters the conformational state of certain integrins, including α5β1 
(27, 28). Plasminogen activation was barely detectable on B2CHO 
cells, either in the presence or absence of Mn2+ (Fig. 1A). In 
contrast, robust uPA-dependent plasminogen activation was ob-
served on α5CHO cells. In the absence of Mn2+, plasminogen ac-
tivation was five-fold higher, increasing to 18-fold higher in the 
presence of Mn2+, with α5β1 in the activated conformation. The 
large difference in plasminogen activation between the two cell 
lines was not a result of differences in the expression of either uPA, 
as determined by quantification of uPA activity in serum-free con-
ditioned medium from the two cell lines (data not shown), or uPAR, 
as shown by uPAR ligand blot (Fig. 1A, inset). Plasminogen acti-
vation was also determined with the cells saturated with exogen-
ously added uPA (Fig. 1B). Under these conditions the rates of plas-
minogen activation were higher (approximately six-fold for 
α5CHO in the presence of Mn2+), and the differences between the 
varying conditions less marked. However, the overall pattern re-
mained the same, with increased plasminogen activation in the 
presence α5β1 and with Mn2+ having a positive effect. The depen-
dence of the observed plasminogen activation on uPAR was dem-
onstrated by the effect of treating the cells with PI-PLC, which re-
duced plasmin generation by greater than 70% in both α5CHO and 
B2CHO cells (data not shown). 
A 
B 
Figure 1: Plasminogen activation on the surface of α5CHO and 
B2CHO cells. A) The activation of plasminogen by endogenous uPA 
bound to uPAR on the surface of CHO cells. Plasmin generation was 
monitored continuously by the hydrolysis of plasmin specific fluorogenic 
peptide substrate. B) Plasminogen activation on cells saturated with ex-
ogenously added pro-uPA. α5CHO (❒), α5CHO + Mn2+ (■), B2CHO 
(❍), B2CHO + Mn2+ (●). “+ Mn2+” indicates that experiments were per-
formed in the presence of 0.1 mM MnCl2. Under all experimental con-
ditions inclusion of amiloride (100 µM), a selective uPA inhibitor of uPA, 
reduced plasminogen activation to undetectable levels. The inset shows a 
uPAR ligand blot of α5CHO and B2CHO cell lysates. The blot was incu-
bated with pro-uPA (2 nM) prior to probing with anti-uPA clone 5 
(10 µg/ml) to allow detection of uPAR. 
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These observations clearly demonstrate that cell surface inte-
grins influence uPAR function. uPAR has no requirement for 
α5β1 to enable it to bind uPA, as shown by many experiments in 
purified and cellular systems, yet its presence here appears to 
promote uPAR-mediated plasminogen activation. Therefore 
these observations can are most readily interpreted as a reduced 
ability of the cells to support uPAR-mediated plasminogen acti-
vation in the absence of α5β1.  
Soluble uPAR is not a ligand for α5β1 on the cell surface 
It has previously been reported that cell-surface integrins can en-
gage with soluble uPAR as a ligand (29). Therefore, we immobi-
lised suPAR on microtitre plates to investigate differences in its 
interaction with cellular integrins by measuring cell adhesion. 
However, neither cell type was found to adhere to immobilised 
suPAR (Fig. 2A). This was not due to steric or other effects 
caused by direct immobilisation of suPAR, as adhesion was not 
observed when suPAR was bound to immobilised anti-uPAR 
antibodies. Addition of exogenous uPA did not promote ad-
hesion (data not shown). Adhesion of cells to the α5β1 ligand fi-
bronectin was used as a control, and as expected α5CHO ad-
hered more avidly than B2CHO (11-fold), and this was enhanced 
by the presence of Mn2+ (Fig. 2A) and abolished by the presence 
of EDTA (data not shown). Therefore, in these experiments, the 
interaction between α5β1 and uPAR that has previously been re-
ported to occur on the cell surface cannot be recapitulated under 
conditions mimicking trans-interactions. 
α5β1 influences uPAR-mediated cell adhesion 
Although neither cell line could adhere to suPAR bound to im-
mobilised antibodies, it was observed in control experiments that 
in the absence of suPAR both cell lines adhered specifically to 
the anti-uPAR monoclonal antibody R4, but not to isotype-
matched control IgG (Fig. 2B) or other anti-uPAR antibodies 
(data not shown). The adhesion of both cell types was increased 
A 
B 
Figure 2: Adhesion of α5CHO and B2CHO to fibronectin, 
suPAR and R4 anti-uPAR monoclonal antibody. CHO cells were 
allowed to adhere for 1 hour at 37oC to wells coated with either fibro-
nectin (10 nM), suPAR (50 nM) or the antibody R4 (50 nM). “+ Mn2+” in-
dicates that experiments were performed in the presence of 0.1 mM 
MnCl2. Cells were fixed and stained for analysis. A) Adhesion of α5CHO 
and B2CHO to fibronectin (closed bars) and suPAR (open bars). Data 
are presented as “% Adhesion” where 100% is defined as the adhesion of 
α5CHO to fibronectin in the presence of MnCl2. B) Adhesion of 
α5CHO and B2CHO to the anti-uPAR R4(closed bars) and an isotype 
matched control IgG (open bars). Data are presented as “% Adhesion” 
where 100% was defined as the adhesion of B2CHO to R4 in the pres-
ence of MnCl2. The adhesion of B2CHO to R4 was typically 60–80% of 
the adhesion of α5CHO to fibronectin. 
A 
B 
Figure 3: Endogenous uPAR on B2CHO cells mediates ad-
hesion to the anti-uPAR antibody R4. A) Immunoprecipitation of 
CHO uPAR by the anti-uPAR monoclonal antibody R4. α5CHO and 
B2CHO cells were extracted in 1% Triton X-100, immunoprecipitated 
with anti-uPAR R4 or isotype matched control and uPAR detected by 
Western blot. Where Mn2+ is indicated 0.1 mM MnCl2 was added to the 
culture media for 24 hours prior to extraction. B) Effect of PI-PLC on 
cell adhesion. α5CHO and B2CHO cells were treated with PI-PLC prior 
to assay of adhesion to R4-coated wells. Cells treated with PI-PLC (open 
bars) are shown in comparison to untreated cells (closed bars).  
“+ Mn2+” indicates that experiments were performed in the presence of 
0.1 mM MnCl2. Data are presented as “% Adhesion” where 100% is 
 defined as the adhesion of B2CHO to R4 in the presence of 0.1 mM 
MnCl2.  
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in the presence of Mn2+, suggesting the involvement of activated 
integrins. However, the adhesion of the B2CHO cells was at least 
three-fold greater than the adhesion of the cells expressing α5β1. 
To demonstrate that endogenous hamster uPAR on the surface 
of CHO cells could recognise the anti-human uPAR antibody R4, 
immunoprecipitation experiments were performed (Fig. 3A). 
uPAR could be immunoprecipitated from both α5CHO and 
B2CHO cells, both in the presence and absence of Mn2+. uPAR 
could also be immunoprecipitated by other anti-human uPAR 
monoclonal antibodies (data not shown). The uPAR-dependence 
of the observed adhesion was also confirmed by treating the cells 
with PI-PLC to remove GPI-anchored uPAR prior to the adhesion 
experiments. PI-PLC reduced the adhesion of B2CHO cells in the 
presence of Mn2+ by more than four-fold, while the adhesion of 
α5CHO cells was unaffected (Fig. 3B). These observations con-
firm that uPAR was responsible for the observed integrin-de-
pendent differential adhesion to the antibody. 
To confirm that the observed adhesion of CHO cells to the anti-
body R4 was integrin dependent, cells were treated with M25, a 
uPAR-binding peptide which has been shown to disrupt uPAR-in-
tegrin interactions in other cell types (9). M25 reduced the adhesion 
of B2CHO cells by up to 85% in a dose-dependent manner (Fig. 4), 
but had a much lesser effect on the adhesion of α5CHO and only at 
high concentrations of peptide. The minor adhesion of both cell 
types in the absence of Mn2+ was unaffected. Therefore, in B2CHO 
cells uPAR-dependent adhesion in the absence of α5β1 is both pro-
moted by Mn2+ and inhibited the M25 peptide. This strongly impli-
cates the involvement of activated integrins other than α5β1 in fa-
cilitating the observed uPAR-dependent adhesion to the anti-uPAR 
antibody. The lack of effect of M25 on the adhesion of α5CHO cells 
is in good agreement with our previous observations with HB2 
breast epithelial cells, in which M25 did not interfere with the 
CD82-induced interaction between α5β1 and uPAR (20). 
Soluble uPAR and uPA do not interact with the 
isolated ectodomain of α5β1 
The observations here, and in our previous study (20), demon-
strate that α5β1 integrin can modulate the interaction of uPAR 
with its ligand uPA in a manner dependent on the activation state 
of the integrin. However, divergent effects were observed in the 
two different experimental systems used. Here, α5-transfected 
CHO cells display increased uPAR-dependent plasminogen acti-
vation, whereas previously, in HB2 cells, transfection with CD82 
led to a strong association of uPAR with α5β1 and a concomitant 
reduction in uPA binding and plasminogen activation. 
In an attempt to determine the molecular basis of these ef-
fects, the interaction between suPAR and recombinant isolated 
Figure 5: Solid phase assays of the interactions between uPAR, 
uPA, α5β1 and fibronectin. Solid phase binding assays were performed 
to measure: A) suPAR binding to immobilised uPA and α5β1-Fc. Binding 
of suPAR (100 nM) to wells coated with either uPA (100 nM) or α5β1-Fc 
(5 nM) was detected with R4 as the primary antibody R4. In samples in-
dicated, equimolar uPA or DFP-uPA was added to the suPAR incubation 
mixture. In all cases the binding of suPAR to α5β1-Fc was significantly dif-
ferent from the binding of suPAR to uPA (p≤0.001). Controls with fibro-
nectin indicated that the integrin was active and able to bind its ligand 
(not shown). B) uPA binding to immobilised suPAR +/- α5β1-Fc/50kDa fi-
bronectin fragment. Binding of uPA (50 nM) to wells coated with suPAR 
(50 nM) was detected using the primary anti-uPA clone 5. In samples in-
dicated, equimolar α5β1-Fc or α5β1-Fc + fibronectin fragment was added 
to the uPA incubation mixture. There were no statistically significant dif-
ferences between the data. The experiments shown were performed in 
the presence of 0.1 mM MnCl2. Data are expressed as “% Binding” with 
100% defined as the binding of uPA and suPAR. 
Figure 4: The uPAR-binding peptide M25 blocks adhesion of 
B2CHO cells to the anti-uPAR antibody R4. α5CHO and B2CHO 
were treated with 10 µM M25 (open bars ), 100 µM M25 (shaded bars) 
or carrier control (solid bars) for 20 minutes at 37oC prior to being 
allowed to adhere to R4-coated wells. After 1 hour at 37oC cells were 
fixed and stained for analysis. Data are presented as “% Adhesion” where 
100% was defined as the adhesion of B2CHO to R4 in the presence of 
0.1mM MnCl2. *, p < 0.02; **, p < 0.006; ***, p = 0.0003. In control experi-
ments M25 was shown to have no direct effect on the interaction be-
tween suPAR and the R4 antibody. 
A 
B 
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ectodomain of human α5β1 was investigated. α5β1-Fc fusion pro-
tein was immobilised on microtitre plates and the binding of 
suPAR determined using the uPAR antibody R4. This ELISA-
type detection format avoids potential problems of direct label-
ling of suPAR modifying key residues of potential functional im-
portance. In control experiments, suPAR bound efficiently to im-
mobilised uPA (Fig. 5A) and fibronectin bound efficiently to 
α5β1-Fc when either protein was immobilised (data not shown). 
However, binding of suPAR to immobilised α5β1-Fc could not be 
detected (Fig. 5A), nor could the binding of α5β1-Fc to immobi-
lised suPAR (data not shown). uPAR-ligand complexes, formed 
by preincubation of suPAR with either uPA or DFP-inactivated 
uPA, also failed to bind to immobilised α5β1-Fc (Fig. 5A). These 
experiments were performed in the presence of Mn2+ to ensure 
that α5β1-Fc was in an active conformation, but the observations 
were unchanged in the presence of EDTA, although as expected 
EDTA prevented the binding of fibronectin to α5β1-Fc and did 
not affect the binding of uPA to suPAR (data not shown). 
As we could not detect an interaction between suPAR and 
α5β1 directly, we investigated whether α5β1 could interfere with 
the interaction between uPA and suPAR. However, the binding of 
uPA to immobilised suPAR was unaffected by the presence of 
either α5β1-Fc or α5β1-Fc in complex with the 50 kDa fibronec-
tin fragment (Fig. 5B). Similarly the binding of suPAR to im-
mobilised uPA was unaffected by the presence of α5β1-Fc (data 
not shown). 
To address whether the inability to detect an interaction be-
tween purified uPAR and α5β1 resulted from artefacts due to pro-
tein immobilisation, proteins were combined in solution and 
complex formation analysed by native PAGE. This non-denatur-
ing technique separates proteins on the basis of their charge as 
well as their hydrodynamic size, and can be used to detect pro-
tein-protein interactions with “band shifts” being observed on 
complex formation (30). This is demonstrated by the observation 
that the complex between uPA and suPAR is clearly distinct from 
the bands due to either protein alone (Fig. 6A). Similarly, when 
α5β1 or α5β1-Fc were combined with the 50 kDa fibronectin 
fragment, an integrin-fibronectin complex was detected (Fig. 
6B). In the case of α5β1 the complex was indicated by the appear-
ance of a new band, whereas the complex between α5β1-Fc and 
the fibronectin fragment was indicated by the disappearance of 
the fibronectin fragment band, and a sharpening of the α5β1 
band. Using this technique there was no evidence for complex 
formation between uPAR and α5β1 as no new bands were de-
tected and the mobility and appearance of the integrin and 
suPAR bands remained unchanged (Fig. 6C). 
The control experiments (Fig. 6A and B) demonstrate that 
this technique can detect interactions of both high affinity (uPA-
uPAR, Kd 0.1–0.3 nM) and low affinity (α5β1-fibronectin, Kd 
0.1–1 µM), but fail to detect a suPAR-α5β1 interaction at reactant 
concentrations of up to 2 µM. However, to ensure that lack of de-
tection of an α5β1-uPAR interaction was not due to complex dis-
sociation during electrophoresis, the effect of α5β1 on uPA-
suPAR complex formation was determined. The mobility of 
suPAR was detected by Western blotting and was unchanged by 
α5β1-Fc, either in the presence or absence of uPA (Fig. 6D). 
Similarly suPAR did not alter the interaction between α5β1-Fc 
and the 50 kDa fibronectin fragment (data not shown). 
The lack of an interaction between suPAR and α5β1 in sol-
ution was further supported by the observation that soluble α5β1 
had no effect on plasminogen activation initiated by pro-uPA 
either in the presence or absence of suPAR (data not shown). 
Discussion 
In the present study we show that α5β1 integrin has a profound in-
fluence on uPAR function, affecting its roles in both pericellular 
proteolysis and cell adhesion. We have shown previously that the 
ability of uPAR to support plasminogen activation at the cell sur-
A 
B 
Figure 6: Native PAGE analysis of the interactions between 
uPAR, uPA, α5β1 and fibronectin. Equimolar (2 µM) combinations of 
uPA, suPAR, α5β1, α5β1-Fc and fibronectin fragment, as indicated, were 
incubated for 10 minutes at 4oC prior to analysis by native PAGE at pH 
8.8. Panels A-C show silver stained gels. D) Western blot performed 
with the anti-uPAR R4. Bands corresponding to α5β1, α5β1-Fc, α5β1 + Fn 
fragment, suPAR, uPA, uPA+suPAR are indicated (A-C). The multiple 
suPAR bands seen in the Western blot (D) result from the differently gly-
cosylated forms in the preparation.  
C 
D 
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face can be markedly affected by other membrane proteins in-
volved in the regulation of cell adhesion. We found that the tet-
raspan protein CD82 reduced the ability of uPAR to bind uPA, 
leading to a 50-fold reduction in plasminogen activation (20). 
However, we also found that the effect of CD82 was indirect, and 
that it promoted a stable interaction between uPAR and α5β1, 
thereby implicating this integrin in the modulation of uPAR 
function. Here we have directly investigated the effect of α5β1, 
both by over-expression in CHO cells and using recombinant 
soluble integrin. Although we find no direct evidence for a mo-
lecular interaction between uPAR and α5β1, the presence of α5β1 
on the cell surface affects uPAR function, both increasing uPAR-
mediated plasminogen activation and decreasing uPAR-me-
diated cell adhesion.  
Plasminogen activation on α5β1-expressing cells was in-
creased by up to 18-fold in comparison to B2CHO cells, despite 
both cell lines expressing equivalent levels of uPAR. This situ-
ation is clearly different to our previous observation of greatly re-
duced plasminogen activation as a consequence of CD82-me-
diated uPAR-α5β1 interactions (20), and consistent with this we 
found no evidence for uPAR-α5β1 interactions in α5CHO cells. 
Other studies have reported that the integrins αMβ2 and αVβ3 can 
increase plasminogen activation. The leukocyte-specific inte-
grin αMβ2 has been observed to bind both uPA and plasminogen 
directly, leading to an increase in plasminogen activation (31, 
32). αVβ3 was also observed to bind uPA directly and to mediate 
plasminogen activation on the surface of uPAR-depleted CHO 
cells (33). Here we found no evidence for direct binding of uPA 
to α5β1, and purified α5β1 had no effect on uPA-catalysed plas-
minogen activation, and therefore similar uPAR-independent 
mechanisms are unlikely to be involved in the observed cellular 
effects of α5β1.  
We also found no evidence for trans-interactions between 
cell surface α5β1 and immobilised suPAR. However, the pres-
ence of α5β1 was observed to alter the adhesion of these cells spe-
cifically to the anti-uPAR monoclonal antibody R4. Although 
not of direct biological relevance, this adhesion gives some in-
sights into the role of integrins in modulating uPAR function. 
The adhesion to the antibody was demonstrated to be uPAR-de-
pendent, as it was abolished by PI-PLC treatment of the cells, 
and the antibody was shown to recognise hamster uPAR in im-
munoprecipitation experiments. This adhesion was also integrin-
dependent as it was greatly promoted in the presence of Mn2+. 
This cooperation between uPAR and integrins suggests that ad-
hesion to the antibody is mediated by interactions between these 
proteins. This conclusion is further supported by the observation 
that the uPAR-binding peptide M25, which has previously been 
shown to disrupt the interaction between uPAR and multiple in-
tegrins (9), effectively abolished this cell adhesion. Therefore, 
the observation that adhesion of the cells expressing α5β1 was re-
duced in comparison to the α5-deficient cells suggests that this 
integrin does not interact with uPAR in a manner supporting this 
adhesion. Furthermore, α5β1 appears to disrupt interactions be-
tween uPAR and integrins endogenously present on these cells 
that do support uPAR-mediated adhesion. 
When comparing the observations here to those we have 
made previously in cells overexpressing CD82 (20), it is appar-
ent that the effects ascribed to α5β1 are divergent, although in 
both cases α5β1 is intimately linked to the regulation of uPAR-
mediated plasminogen activation. We previously showed that 
CD82 promoted stable interactions between uPAR and α5β1, 
which could be detected by co-immunoprecipitation, leading to a 
reduction in uPAR-mediated plasminogen activation. In the pres-
ent study, despite overexpression of  α5β1, there is no evidence 
for a similar stable association, and plasminogen activation is not 
reduced by α5β1. Therefore, in CHO cells there is no evidence 
that α5β1 interacts with uPAR to directly regulate plasminogen 
activation. The reduced plasminogen activation observed in the 
absence ofα5β1 may possibly involve interactions between uPAR 
and integrins other than α5β1 present on the surface of these cells, 
i.e. those that support uPAR-mediated cell adhesion. 
Evidence for interactions between uPAR and α5β1 has pre-
viously come from a variety of observations. Adhesion of 
α5β1-expressing cells to immobilised suPAR in an activation-de-
pendent manner has been demonstrated, and interpreted as trans-
interactions between the proteins (although this adhesion was 
considered to be weaker than that observed on over-expression 
of several other β1 and β3 integrins) (29). Adhesion of the same 
cells to uPA was found to be dependent on both uPAR and α5β1, 
suggesting lateral or cis uPAR-α5β1 interactions (18). The bind-
ing of radio-iodinated suPAR to purified α5β1 has also been dem-
onstrated to require the presence of uPA (18), although binding 
of biotinylated suPAR to immobilised purified α5β1 in the ab-
sence of uPA has also been demonstrated (10). In the present 
study we have found no adhesion of either α5CHO or B2CHO 
cells to suPAR, either directly or indirectly immobilised via an 
antibody, and we have been unable to detect any interaction be-
tween the purified proteins, either in the presence or absence of 
ligands for both receptors, using a range of techniques in which 
suPAR is neither labelled nor chemically modified. It should be 
noted that biotinylation of suPAR is known to decrease its spe-
cific binding capacity and to increase non-specific binding (G. 
Høyer-Hansen, personal communication). However, our inabil-
ity to detect an interaction between uPAR and α5β1 in purified 
systems does not exclude the occurrence of direct interactions on 
the cell surface where high local concentrations of the proteins 
could promote cis-interactions, for example in lipid rafts (34). 
uPAR and α5β1 have been shown to co-imunoprecipitate in cer-
tain tumour cells (16), and we have previously observed this in 
the presence of CD82 (12, 20); although not here in α5CHO 
cells. Indirect evidence for uPAR-α5β1 interactions comes from 
observations on the effect of uPAR on various aspects of α5β1 
function, including signalling, migration and fibronectin matrix 
assembly (11, 12, 16–19, 35). In many of these examples, uPA 
binding to uPAR is thought to promote the interaction with α5β1. 
However, our previous observations on the effect of CD82 are 
not consistent with this mechanism, as uPAR in the resulting 
stable complex with α5β1 was unable to bind uPA (20). An impor-
tant aspect of the two model systems that we have used is that we 
are observing the function of endogenously expressed uPAR, 
and not the consequences of uPAR over-expression as often used 
in other studies. 
Although we have interpreted our observations as implicat-
ing non-α5 integrins in increasing uPAR-mediated cell adhesion, 
and possibly in interacting with uPAR and reducing uPAR-me-
diated plasminogen activation, we have not identified these inte-
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grins. How these putative interactions might be modified by α5β1 
is unclear, but, from our previous observations with CD82 (20) 
and the known role of tetraspanins in modulating the localisation 
and functional activity of integrins (36, 37), a role for these pro-
teins in the observed effects is possible. 
A major conclusion that can be drawn from the data pres-
ented here, and which is supported by our previous observations 
(20), is that the presence of uPAR on the cell surface, even in the 
presence of excess uPA, does not inevitably lead to uPA binding 
and plasminogen activation. We have previously referred to 
uPAR that is unavailable for uPA binding as “cryptic”, while 
others have termed it “latent” (38), and a rational basis for this 
can be proposed based on the crystal structure of uPAR. The 
structure of uPAR has been solved both in complex with a pep-
tide antagonist of uPA binding (39) and with the amino-terminal 
fragment of uPA (40). These structures differ in the relative 
orientation of the three homologous domains of uPAR, all of 
which are necessary for uPA binding (41, 42), suggesting a sig-
nificant degree of conformational flexibility in uPAR that is con-
trolled by ligand binding (38). Therefore, it could be envisaged 
that interactions between uPAR and integrins, including α5β1, 
could alter the conformation of uPAR to influence uPA binding. 
Direct evidence that conformational changes in uPAR can abol-
ish uPA binding comes from the observation that certain anti-
uPAR monoclonal antibodies can non-competitively dissociate 
preformed uPA-uPAR complexes (43). On the cell surface such 
conformational changes in uPAR could result from either direct 
interactions with integrins or integrin-mediated clustering of 
uPAR.  
In summary we have shown that the integrin α5β1 plays a key 
role in the regulation of uPAR function at the cell surface, affect-
ing its role both as a receptor mediating plasminogen activation 
and as a putative adhesion receptor, and extending our previous 
observations (20). Together with the known role of uPAR-inte-
grin interactions in modulating integrin function, these observa-
tions demonstrate that bi-directional communication exists be-
tween these two protein systems involved in pericellular pro-
teolysis and cell adhesion. This communication has the potential 
to be dynamic, as no irreversible or covalent changes to the pro-
teins are involved, and may have important role in mediating in-
vasive cell migration. Understanding how the apparently pro-
miscuous interactions between uPAR and integrins at the cell 
surface are regulated will require further investigation. 
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What is known about this topic? 
− uPAR has a key role in mediating plasminogen activation 
on the cell surface. 
− Interactions between uPAR and adhesion receptors of the 
integrin family, including α5β1, interact with uPAR on the 
cell surface to alter integrin function. 
− uPAR-mediated plasminogen activation is down-regulated 
by CD82, an integrin-associated tetraspanin protein, by 
redistributing α5β1 to colocalise and associate with uPAR 
on the cell surface . 
What does this paper add? 
− We show that expression of α5β1 in Chinese hamster 
ovary cells leads both to an increase in uPAR-mediated 
plasminogen activation and a decrease in uPAR- and inte-
grin-dependent adhesion to an anti-uPAR monoclonal 
antibody. 
− Despite these effects, direct interactions between uPAR 
and α5β1 could not be found, either on the cell surface or 
using purified proteins in solution. 
− α5β1 and other integrins cooperate to regulate uPAR- 
mediated proteolysis, and also uPAR-mediated cell ad-
hesion, potentially influencing invasive cell migration .
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